Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of GFH375 in KRAS G12D-mutant advanced solid tumors
CTR20242253Phase 2Active
- Sponsor
- GenFleet Therapeutics
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GFH375 in Nonhematologic neoplasms, sponsored by GenFleet Therapeutics. Started Jul 2024; status: active.
02
Drugs
GFH375
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20242253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242253.